ISDS Case Map
medicines
India is fast-tracking the review of the ASEAN-India Trade in Goods Agreement (AITIGA) to address a significant trade deficit and secure better market access for its pharmaceutical and agricultural exports.
The India–New Zealand Free Trade Agreement (FTA), signed in April 2026, grants 100% duty-free access for over 8,200 Indian export lines and includes a USD 20 billion investment commitment to Indian pharmaceuticals, medical devices, and engineering exports.
The Civil Society Coalition for Economic Justice (Koalisi MKE) urges President Prabowo Subianto not to ratify the reciprocal trade agreement (ART) between Indonesia and the United States (US) signed on February 19, 2026. The 19% tariff reduction obtained by Indonesia in this agreement is not commensurate with the surrender of the country's sovereignty to US interests.
Delhi Network of Positive People (DNP+) and Médecins Sans Frontières (MSF) notes positively that the intellectual Property (IP) chapter of this trade deal largely preserves India’s public health safeguards and does not include any harmful provisions that go beyond the World Trade Organization’s TRIPS agreement, such as data exclusivity or patent term extensions.
The US-Argentina deal represents a new low in using US trade policy to bully countries into adopting intellectual property rules that expand Big Pharma’s monopoly power at the expense of access to affordable medicines.
The Working Group points out that the European Commission's press release states the agreement provides for a high level of protection and enforcement of Intellectual Property rights, including copyright, trademarks, designs, trade secrets and plant variety rights.
The recent US trade deal restricts the rights of Malaysia’s National Pharmaceutical Regulatory Agency (NPRA), to conduct its own assessments of safety, efficacy and quality, reflecting national health needs and regulatory priorities.
The administration said it would pursue similar deals with other countries that have not yet locked in trade agreements with the US to correct a longstanding gripe Trump has had with wealthy European nations that he says pay too little for medicines.
The United States announced a deal with Britain for zero tariffs on pharmaceutical products and medical technology which will lead to Britain spending more on medicines.
A flurry of new tariff announcements on pharma, trucks and movies have left British officials scrambling to keep up.
